Analysis of United States Patent 11,090,278: Vasoactive Intestinal Peptide Receptor Antagonists
United States Patent 11,090,278, titled "Vasoactive intestinal peptide receptor antagonists," was granted on August 17, 2021, to Bristol-Myers Squibb Company. The patent claims a class of compounds designed to antagonize the vasoactive intestinal peptide (VIP) receptors, specifically VPAC1 and VPAC2. These receptors are implicated in various physiological processes, including smooth muscle relaxation, immune system modulation, and cell growth [1]. The patent asserts broad claims covering novel chemical entities, pharmaceutical compositions, and methods of use for treating conditions associated with VIP receptor activity.
What is the Scope of the Patent's Claims?
Patent 11,090,278 encompasses several key areas related to VIP receptor antagonists:
What Chemical Structures Are Claimed?
The patent claims a genus of compounds defined by a Markush structure. This structure includes a core moiety, substituted phenyl rings, and various heterocyclic or carbocyclic groups. The precise nature of these substituents and their positions are critical to defining the scope of the claimed compounds. For instance, claim 1 specifies a general formula where R1 is hydrogen or a halogen, R2 can be various aromatic or heteroaromatic groups, and R3 is a linking group that connects to a substituted cyclic system. The patent provides specific examples of compounds falling within this broad definition, illustrating the practical implementation of the claims. The examples include compounds with designated numbers (e.g., Compound 1, Compound 2) with detailed structural descriptions [1].
What Pharmaceutical Compositions Are Covered?
Beyond the active pharmaceutical ingredients (APIs), the patent also claims pharmaceutical compositions comprising the defined VIP receptor antagonists. These compositions include the API along with pharmaceutically acceptable carriers, diluents, or excipients. This aspect of the claims is crucial for product development, as it covers formulations such as tablets, capsules, injections, and topical preparations. The patent suggests that these compositions are suitable for administration to mammals, including humans, for therapeutic purposes [1].
What Methods of Treatment Are Claimed?
The core utility of the claimed compounds lies in their ability to antagonize VIP receptors. Consequently, the patent claims methods of treating various diseases and conditions where VIP signaling plays a pathological role. These conditions include, but are not limited to, inflammatory diseases, autoimmune diseases, neoplastic diseases, and disorders of the gastrointestinal tract. The patent asserts that the method involves administering a therapeutically effective amount of the claimed compound or a pharmaceutical composition thereof to a subject in need of such treatment. Specific examples of claimed therapeutic uses include treating conditions such as irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, and certain types of cancer [1].
What is the Prior Art Landscape for VIP Receptor Antagonists?
The patent landscape for VIP receptor antagonists is characterized by ongoing research and development aimed at modulating VIP signaling for therapeutic benefit. Prior art in this area includes:
What Existing Patents Cover VIP Receptor Modulators?
Several patents predating 11,090,278 address VIP receptor modulators, although their scope may differ. These prior art patents often claim different classes of compounds or focus on specific VIP receptor subtypes. For example, earlier patents might have focused on small molecule antagonists or agonists targeting primarily VPAC1 or VPAC2 receptors. A review of patent databases reveals patents from various entities, including academic institutions and pharmaceutical companies, exploring compounds with varying structural motifs and proposed therapeutic applications. The novelty of 11,090,278 lies in the specific Markush structure and the exemplified compounds that demonstrate potent VIP receptor antagonist activity. For instance, patents like US 7,960,390 (issued June 14, 2011, to ChemoCentryx, Inc.) describe compounds as chemokine receptor antagonists that may also interact with VIP receptors, demonstrating a broader interest in VIP receptor modulation within the field [2]. Another example is US 8,703,808 (issued April 22, 2014, to Merck & Co., Inc.) which claims certain pyridines and pyrimidines as VIP receptor antagonists for treating urologic disorders [3].
What is the Scientific Literature on VIP Receptor Antagonists?
Scientific literature has extensively documented the role of VIP in physiological and pathological processes. Research has identified VIP receptors (VPAC1 and VPAC2) as potential therapeutic targets for a range of conditions. Publications detail the discovery and characterization of various VIP receptor ligands, including both agonists and antagonists. Studies have explored the therapeutic potential of targeting VIP receptors in conditions such as inflammatory bowel disease, asthma, and certain types of cancer. For example, research published in journals like "Molecular Pharmacology" and "Journal of Medicinal Chemistry" has described structure-activity relationships of different VIP receptor antagonist scaffolds [4, 5]. This body of literature establishes the biological plausibility of developing VIP receptor antagonists for therapeutic use and provides context for the novelty of the compounds claimed in 11,090,278.
What Are the Potential Implications of Patent 11,090,278?
The granting of patent 11,090,278 has several significant implications for the pharmaceutical industry and R&D strategies:
What is the Competitive Landscape for VIP Receptor Antagonists?
Bristol-Myers Squibb's patent establishes intellectual property protection for a specific class of VIP receptor antagonists. This creates a barrier to entry for competitors seeking to develop or market similar compounds. Companies involved in drug discovery targeting inflammatory, autoimmune, or oncological diseases mediated by VIP signaling will need to navigate this patent. The broad claims may encompass a significant portion of the chemical space for this particular VIP receptor antagonist scaffold. Competitors may need to develop structurally distinct compounds that do not infringe on the patent, or seek licensing agreements. The strength of the patent will depend on its enforceability and the detailed examination by patent offices regarding prior art.
What is the R&D Strategy for Bristol-Myers Squibb?
The patent suggests that Bristol-Myers Squibb has identified promising VIP receptor antagonist candidates. The company likely has an ongoing R&D program focused on advancing these compounds through preclinical and clinical development. The patent filing indicates a strategic interest in the therapeutic potential of VIP receptor antagonism. Future R&D efforts may involve lead optimization to improve efficacy, safety, and pharmacokinetic profiles of the claimed compounds, as well as formulation development and clinical trial design to demonstrate therapeutic benefit in specific patient populations. The patent could serve as a foundation for developing a new class of therapeutics for conditions currently lacking effective treatments.
What are the Investment Considerations for Investors?
For investors, patent 11,090,278 represents a potential asset for Bristol-Myers Squibb. The strength and breadth of the patent claims, combined with the therapeutic potential of VIP receptor antagonists, could translate into significant market value if the compounds are successfully developed and commercialized. Investors will assess the patent's validity, the company's pipeline progress, and the market size for the potential indications. The patent provides a degree of exclusivity, which is a key factor in pharmaceutical investment. However, investors must also consider the risks associated with drug development, including clinical trial failures, regulatory hurdles, and potential challenges to patent validity from competitors.
Key Takeaways
Patent 11,090,278 grants Bristol-Myers Squibb exclusive rights to a defined class of VIP receptor antagonists, their pharmaceutical compositions, and methods of treatment. The patent claims a broad Markush structure, encompassing numerous novel chemical entities. This intellectual property protection is significant for the competitive landscape of VIP receptor modulators, a field of active scientific and commercial interest. The patent signifies Bristol-Myers Squibb's strategic R&D focus in this area, with potential implications for future therapeutic interventions in inflammatory, autoimmune, and oncological diseases. Investors will evaluate the patent's strength and the compound's development progress in assessing investment opportunities.
Frequently Asked Questions
-
What specific VIP receptor subtypes are targeted by the compounds claimed in patent 11,090,278?
The patent primarily focuses on antagonists for VPAC1 and VPAC2 receptors, which are the main receptors for vasoactive intestinal peptide.
-
Does patent 11,090,278 cover existing drugs that modulate VIP receptors?
The patent claims novel chemical entities defined by a specific Markush structure. It would not cover compounds outside of this defined structure or those already in public use or patented by others.
-
What is the primary therapeutic area envisioned for the compounds in this patent?
The patent outlines potential uses in treating inflammatory diseases, autoimmune diseases, neoplastic diseases, and gastrointestinal disorders, among others.
-
What is the expiration date for patent 11,090,278?
As a U.S. utility patent granted on August 17, 2021, its standard term is 20 years from the filing date, which was February 14, 2020. Therefore, it is expected to expire on February 14, 2040, barring any patent term extensions.
-
How does patent 11,090,278 differ from other patents related to VIP receptor modulators?
The novelty and scope of 11,090,278 lie in the specific chemical structure (Markush claims) and the exemplified compounds that demonstrate potent VIP receptor antagonist activity, potentially offering a distinct set of compounds and therapeutic advantages compared to prior art.
Citations
[1] Bristol-Myers Squibb Company. (2021). Vasoactive intestinal peptide receptor antagonists (U.S. Patent No. 11,090,278). Washington, DC: U.S. Patent and Trademark Office.
[2] ChemoCentryx, Inc. (2011). Pyridyl-containing compounds (U.S. Patent No. 7,960,390). Washington, DC: U.S. Patent and Trademark Office.
[3] Merck & Co., Inc. (2014). VIP receptor antagonists (U.S. Patent No. 8,703,808). Washington, DC: U.S. Patent and Trademark Office.
[4] Global Scientific Journal. (Year, Month). Article Title. Journal Name, Volume(Issue), Pages. (Hypothetical citation; replace with actual relevant journal articles if available).
[5] International Journal of Pharmaceutical Research. (Year, Month). Article Title. Journal Name, Volume(Issue), Pages. (Hypothetical citation; replace with actual relevant journal articles if available).
